Cabozantinib
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DRUG-CABOZANTINIB |
|---|---|
| Art | Arzneimittel |
| Aliase | CabometyxCometriqКабозантиніб |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Erkrankungen | DIS-HCC DIS-MTC DIS-PHEOCHROMOCYTOMA DIS-RCC |
| Quellen | SRC-NCCN-HCC-2025 SRC-NCCN-KIDNEY-2025 SRC-NCCN-THYROID-2025 |
Drug Facts
| Klasse | Multikinase-Inhibitor (MET, VEGFR1-3, RET, AXL, KIT, FLT3, ROS1) |
|---|---|
| Verfahren | Orale multi-targeted TKI hemmende MET, VEGFR1-3, RET, AXL, KIT, FLT3 und ROS1. Zugelassen für das medulläre Schilddrüsenkarzinom (EXAM-Studie — Kapselformulierung Cometriq 140 mg), Nierenzellkarzinome (METEOR / CABOSUN — Tablettenformulierungen Cabometyx 60 mg), HCC (CELESTIAL 2L) und DTC (COSMIC-311). Aktivität in MTC unabhängig vom RET-Mutationsstatus — Option für RET-WT MTC, wenn selektive RET Inhibitoren nicht geeignet sind. |
| Typische Dosierung | Medullary thyroid carcinoma (Cometriq capsules): 140 mg PO once daily on empty stomach (≥1 h before / ≥2 h after food). RCC / HCC / DTC (Cabometyx tablets): 60 mg PO once daily on empty stomach. Capsule and tablet formulations are NOT bioequivalent. |
| Ukraine registriert | Falsch |
| NSZU erstattet | Falsch |
| Ukraine zuletzt überprüft | 2026-04-27 |
Warnungen
- Perforation GI / Fistel
- Schwere / tödliche Blutungen
Anmerkungen
EXAM (Schoffski 2012, MTC): cabozantinib 140 mg vs placebo improved PFS 11.2 vs 4.0 mo; OS benefit in M918T-mutant subgroup. ZETA (vandetanib) is the alternative MTC multikinase TKI; both predate RET-selective era. Modern preferred sequence in advanced RET-mutant MTC: selpercatinib > pralsetinib > cabozantinib / vandetanib (toxicity pushes selectives first). For RET-WT MTC (RAS-mutant or unknown), cabozantinib retains primary role. Capsule (Cometriq) and tablet (Cabometyx) are NOT interchangeable — different bioavailability per FDA prescribing information.
Verwendet von
Anwendungsgebiet
IND-PHEO-METASTATIC-1L-CABOZANTINIB- IND-PHEO-METASTATIC-1L-CABOZANTINIB
Therapieschema
REG-CABOZANTINIB-HCC- Cabozantinib (HCC, 2L)REG-CABOZANTINIB-MTC-1L- Cabozantinib Monotherapie (fortgeschrittene/progressive RET-WT MTC, 1L; oder RET-mutant, wenn RET-se...REG-CABOZANTINIB-PHEO- Cabozantinib monotherapy (metastatic non-MIBG-avid pheochromocytoma/paraganglioma, altern...REG-CABOZANTINIB-RCC- Cabozantinib Monotherapie (RCC, 2L)REG-NIVO-CABO-RCC- Nivolumab + Cabozantinib (RCC, 1L)